Dr. Hébert was born in Montréal in 1974. He studied biotechnology, and obtained his Ph.D. in Cellular and Molecular Biology at Laval University in 2003. He then completed a postdoctoral fellowship in human genetics at the Katholieke Universiteit Leuven in Belgium. In 2009, he was recruited as Assistant Professor at Laval University. Dr. Hébert is currently an Associate Professor in the Department of Psychiatry and Neuroscience at Laval University. He is also a researcher (group leader) in the Neuroscience Unit of the Research Center of the CHU de Québec – Laval University.

Dr. Hébert’s work focuses on the biological and molecular mechanisms that cause neuronal death and dementia. Specifically, his research team studies the role of micro-RNAs in the development, diagnosis, and treatment of neurodegenerative diseases such as Alzheimer’s disease, frontotemporal dementia, and Huntington’s disease. Micro-RNAs are small molecules in the body that are similar to DNA and regulate the level of proteins. Dr. Hébert’s pioneering research has shown that many micro-RNAs are deregulated in patients with Alzheimer’s disease, and other types of dementia. Curiously, a number of these molecules can reproduce the pathological and clinical symptoms of dementia in biological models on their own, such as cultured neurons and mice. Dr. Hébert also uses the postmortem human brain as an indispensable tool for his research.

Recently, his work on a potential treatment for Alzheimer’s disease was presented by Le Soleil, the FM93 radio station, and The Alzheimer’s Society of Canada’s Website.

Dr. Hébert has received various awards, including the Alzheimer’s Society of Saskatchewan’s Young Investigator Grant (2010) and the FRQS Junior Research Scholar Career Award (2011, 2014). He has been a spokesperson for the Alzheimer’s Society of Canada (2011). In addition to his commitment to teaching, he regularly participates in various evaluation committees and conferences. Finally, he helps organize events and promote basic Canadian research on Alzheimer’s disease, and related dementias.

CHUL
2705, boulevard Laurier
P-09800
Québec, Québec
Canada G1V 4G2
+1 418-525-4444, extension 49233
+1 418-654-2753
Sebastien.Hebert@crchudeq...

Latest news

75 entries « ‹ 1 of 8 › »

Petry S, Keraudren R, Nateghi B, Loiselle A, Pircs K, Jakobsson J, Sephton C, Langlois M, St-Amour I, Hébert SS

Widespread alterations in microRNA biogenesis in human Huntington's disease putamen

Journal Article

Acta Neuropathol Commun, 10 (1), 2022.

Abstract | Links:

Petry S, Nateghi B, Keraudren R, Sergeant N, Planel E, Hébert SS, St-Amour I

Differential Regulation of Tau Exon 2 and 10 Isoforms in Huntington's Disease Brain

Journal Article

Neuroscience, 2022.

Abstract | Links:

Guisle I, Canet G, Pétry S, Fereydouni-Forouzandeh P, Morin F, Kérauden R, Whittington RA, Calon F, Hébert SS, Planel E

Sauna-like conditions or menthol treatment reduce tau phosphorylation through mild hyperthermia

Journal Article

Neurobiol Aging, 113 , 2022.

Abstract | Links:

Pircs K, Drouin-Ouellet J, Horváth V, Gil J, Rezeli M, Garza R, Grassi DA, Sharma Y, St-Amour I, Harris K, Jönsson ME, Johansson PA, Vuono R, Fazal SV, Stoker T, Hersbach BA, Sharma K, Lagerwall J, Lagerström S, Storm P, Hébert SS, Marko-Varga G, Parmar M, Barker RA, Jakobsson J

Distinct subcellular autophagy impairments in induced neurons from patients with Huntington's disease

Journal Article

Brain, 145 (9), 2022.

Abstract | Links:

Eysert F, Coulon A, Boscher E, Vreulx AC, Flaig A, Mendes T, Hughes S, Grenier-Boley B, Hanoulle X, Demiautte F, Bauer C, Marttinen M, Takalo M, Amouyel P, Desai S, Pike I, Hiltunen M, Chécler F, Farinelli M, Delay C, Malmanche N, Hébert SS, Dumont J, Kilinc D, Lambert JC, Chapuis J

Correction to: Alzheimer's genetic risk factor FERMT2 (Kindlin-2) controls axonal growth and synaptic plasticity in an APP-dependent manner

Journal Article

Mol Psychiatry, 26 (10), 2021.

| Links:

Eysert F, Coulon A, Boscher E, Vreulx AC, Flaig A, Mendes T, Hughes S, Grenier-Boley B, Hanoulle X, Demiautte F, Bauer C, Marttinen M, Takalo M, Amouyel P, Desai S, Pike I, Hiltunen M, Chécler F, Farinelli M, Delay C, Malmanche N, Hébert SS, Dumont J, Kilinc D, Lambert JC, Chapuis J

Alzheimer's genetic risk factor FERMT2 (Kindlin-2) controls axonal growth and synaptic plasticity in an APP-dependent manner

Journal Article

Mol Psychiatry, 26 (10), 2021.

Abstract | Links:

Boscher E, Goupil C, Petry S, Keraudren R, Loiselle A, Planel E, Hébert SS

MicroRNA-138 Overexpression Alters Aβ42 Levels and Behavior in Wildtype Mice

Journal Article

Front Neurosci, 14 , 2020.

Abstract | Links:

Boscher E, Hernandez-Rapp J, Petry S, Keraudren R, Rainone S, Loiselle A, Goupil C, Turgeon A, St-Amour I, Planel E, Hebert SS

Advances and Challenges in Understanding MicroRNA Function in Tauopathies: A Case Study of miR-132/212

Journal Article

Front Neurol, 11 , 2020.

Abstract | Links:

Guisle I, Gratuze M, Petry S, Morin F, Keraudren R, Whittington RA, Hebert SS, Mongrain V, Planel E

Circadian and sleep/wake-dependent variations in tau phosphorylation are driven by temperature

Journal Article

Sleep, 43 (4), 2020.

Abstract | Links:

Belleville S, LeBlanc AC, Kergoat MJ, Calon F, Gaudreau P, Hébert SS, Hudon C, Leclerc N, Mechawar N, Duchesne S, Gauthier S,

The Consortium for the early identification of Alzheimer's disease-Quebec (CIMA-Q)

Journal Article

Alzheimers Dement (Amst), 11 , 2019.

Abstract | Links:

75 entries « ‹ 1 of 8 › »
Signaler des ajouts ou des modifications

Active projects

  • Importance of non-canonical microRNAs in the mammalian brain, from 2020-04-01 to 2025-03-31
  • Preclinical safety, pharmacokinetics, pharmacodynamics, and efficiency of microRNA oligonucleotides for Alzheimer's disease, from 2020-03-01 to 2025-03-31
  • Preclinical safety, pharmacokinetics, pharmacodynamics, and efficiency of microRNA oligonucleotides for Alzheimer's disease, from 2022-04-01 to 2027-03-31

Recently finished projects

  • Étude in vivo des microARNs dans les maladies neurodégénératives, from 2019-07-01 to 2022-06-30
  • microRNA-132: from underlying mechanism of neurodegeneration to therapeutic application in Huntington’s disease, from 2017-04-01 to 2022-03-31
Data provided by the Université Laval research projects registery